Yuanyi Wise Tech (Ningbo) Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.